Indoleamine 2,3-dioxygenase (IDO) inhibitor (IC50 = 7 μM); disrupts tryptophan catabolism. Enhances the antitumor and antiviral immunoresponses of CD8+ T-cells in vitro. Reduces tumor volume in mice with xenografts overexpressing IDO.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||1.09||5mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 218.25. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.58 mL||22.91 mL||45.82 mL|
|5 mM||0.92 mL||4.58 mL||9.16 mL|
|10 mM||0.46 mL||2.29 mL||4.58 mL|
|50 mM||0.09 mL||0.46 mL||0.92 mL|
References are publications that support the products' biological activity.
Nakamura et al (2015) Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice. Int.J.Hematol. 102 327 PMID: 26243621
Rytelewski et al (2014) Suppression of immunodominant antitumor and antiviral CD8+ T cell responses by indoleamine 2,3-dioxygenase. PLoS One 9 e90439 PMID: 24587363
If you know of a relevant reference for 1-Methyl-D-tryptophan, please let us know.
View Related Products by Product Action
Keywords: 1-Methyl-D-tryptophan, supplier, 1, MT, Indoleamine, 2,3-dioxygenase, IDO, inhibitors, inhibits, cancer, immunology, 1MT, IDO, IDO, Tocris Bioscience
Citations for 1-Methyl-D-tryptophan
Citations are publications that use Tocris products.
Currently there are no citations for 1-Methyl-D-tryptophan. Do you know of a great paper that uses 1-Methyl-D-tryptophan from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Cancer Metabolism Poster
Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the main targets for cancer metabolism researchers. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways. These distinct metabolic circuits could provide viable cancer therapeutic targets.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.